Literature DB >> 11454718

Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.

S A Nicholson1, N T Okby, M A Khan, J A Welsh, M G McMenamin, W D Travis, J R Jett, H D Tazelaar, V Trastek, P C Pairolero, P G Corn, J G Herman, L A Liotta, N E Caporaso, C C Harris.   

Abstract

Overexpression of E2F-1 induces apoptosis by both a p14ARF-p53- and a p73-mediated pathway. p14ARF is the alternate tumor suppressor product of the INK4a/ARF locus that is inactivated frequently in lung carcinogenesis. Because p14ARF stabilizes p53, it has been proposed that the loss of p14ARF is functionally equivalent to a p53 mutation. We have tested this hypothesis by examining the genomic status of the unique exon 1beta of p14ARF in 53 human cell lines and 86 primary non-small cell lung carcinomas and correlated this with previously characterized alterations of p53. Homozygous deletions of p14ARF were detected in 12 of 53 (23%) cell lines and 16 of 86 (19%) primary tumors. A single cell line, but no primary tumors, harbored an intragenic mutation. The deletion of p14ARF was inversely correlated with the loss of p53 in the majority of cell lines (P = 0.02), but this relationship was not maintained among primary tumors (P = 0.5). E2F-1 can also induce p73 via a p53-independent apoptotic pathway. Although we did not observe inactivation of p73 by either mutation or DNA methylation, haploinsufficiency of p73 correlated positively with either p14ARF or p53 mutation or both (P = 0.01) in primary non-small cell lung carcinomas. These data are consistent with the current model of p14ARF and p53 interaction as a complex network rather than a simple linear pathway and indicate a possible role for an E2F-1-mediated failsafe, p53-independent, apoptotic pathway involving p73 in human lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454718

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2021-01-03       Impact factor: 3.396

2.  Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus.

Authors:  K Yamazaki; M Hasegawa; I Ohoka; K Hanami; A Asoh; T Nagao; I Sugano; Y Ishida
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

Review 3.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

Review 4.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

5.  ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Authors:  S E Busch; R D Moser; K E Gurley; K S Kelly-Spratt; H D Liggitt; C J Kemp
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

6.  Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.

Authors:  Michael W Harr; Timothy G Graves; Erin L Crawford; Kristy A Warner; Cheryl A M Reed; James C Willey
Journal:  Mol Cancer       Date:  2005-07-13       Impact factor: 27.401

Review 7.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Authors:  P Meng; R Ghosh
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

8.  Defined factors to reactivate cell cycle activity in adult mouse cardiomyocytes.

Authors:  Justin Judd; Jonathan Lovas; Guo N Huang
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.